Quality of care delivered by fee-for-service and DRG hospitals in Switzerland in patients with community-acquired pneumonia

Swiss Medical Weekly

Volumn 141, Issue JULY, 2011, Pages

  Schuetz, Philipp ^a,b   Albrich, Werner C ^b   Suter, Isabelle ^c   Hug, Balthasar L ^c   Christ Crain, Mirjam ^c   Holler, Thomas ^b   Henzen, Christoph ^d   Krause, Martin ^e   Schoenenberger, Ronald ^f   Zimmerli, Werner ^b   Mueller, Beat ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d LUZERNER KANTONSSPITAL   (Switzerland)

^e Kantonsspital Muensterlingen   (Switzerland)

^f Buergerspital   (Switzerland)

Author keywords

As fee for service; Community acquired pneumonia; Diagnosis related group; DRG; Length of stay; Outcome; Quality of care

Indexed keywords

ADULT; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; DIAGNOSIS RELATED GROUP; DISEASE SEVERITY; FOLLOW UP; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL FEE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SATISFACTION; PNEUMONIA SEVERITY INDEX; POST HOC ANALYSIS; QUALITY OF LIFE; REIMBURSEMENT; RETROSPECTIVE STUDY; SWITZERLAND; AGED; COMMUNICABLE DISEASE; FEMALE; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; STATISTICS;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS-RELATED GROUPS; FEE-FOR-SERVICE PLANS; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT SATISFACTION; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX; SWITZERLAND;

EID: 80052198354     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13228     Document Type: Article

References (29)

1. Klauss G, Staub L, Widmer M, Busato A. Hospital service areas - a new tool for health care planning in Switzerland. BMC health services research. 2005;5:33.
2. Busato A, von Below G. The implementation of DRG-based hospital reimbursement in Switzerland: A population-based perspective. Health Res Policy Syst. 2010;8:31.
3. Fischer W. Die DRG Familie. CH-9116 Wolfertswil, Switzerland: ZIM-Verlag. 2008.
4. Hervis RM. Impact of DRGs on the medical profession. Clin Lab Sci. 1993;6(3):183-5. (Pubitemid 23183335)
5. Beaty L. Understanding diagnostic related groups (DRGs) and inpatient hospital reimbursement. Gastroenterol Nurs. 2005;28(5):363-8.
6. Rosenthal MB. Beyond pay for performance - emerging models of provider-payment reform. N Engl J Med. 2008;359(12):1197-200.
7. Rosenthal MB. What works in market-oriented health policy? N Engl J Med. 2009;360(21):2157-60.
8. Donaldson C, Magnussen J. DRGs: the road to hospital efficiency. Health Policy. 1992;21(1):47-64.
9. Pretto M, Spirig R, Kaelin R, Muri-John V, Kressig RW, Suhm N. Outcomes of elderly hip fracture patients in the Swiss healthcare system: A survey prior to the implementation of DRGs and prior to the implementation ofa Geriatric Fracture Centre. Swiss Med Wkly. 2010;140:w13086.
10. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. Jama. 2009;302(10):1059-66.
11. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC health services research. 2007;7:102.
12. Albrich WC, Dusemund F, Ruegger K, Christ-Crain M, Zimmerli W, Bregenzer T, et al. Enhancement of CURB65 score with Pro-Adrenomedullin (CURB65-A) for outcome prediction in Respiratory Tract Infections: Derivation of a Clinical Algorithm. BMC infectious diseases. 2011;11:112.
13. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-9.
14. Schuetz P, Christ-Crain M, Albrich W, Zimmerli W, Mueller B. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence. 2010;1 (2):88-92.
15. Schuetz P, Christ-Crain M, Zimmerli W, Mueller B. Repeated measurements of endothelin-1 precursor peptides predict the outcome in community-acquired pneumonia. Intensive Care Med. 2011;37(6):970-80. Epub 2011 Mar 11.
16. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in community-acquired pneumonia. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2011;37(2):384-92.
17. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Critical care (London, England). 2010;14(3):R106.
18. Vazquez M, Jockers K, Christ-Crain M, Zimmerli W, Muller B, Schuetz P. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: A prospective validation study. Int J Cardiol. 2010 Nov 18.
19. Baehni C, Meier S, Spreiter P, Schild U, Regez K, Bossart R, et al. Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC pulmonary medicine. 2010;10:12.
20. Spreiter P, Meier S, Baehni C, Schild U, Regez K, Bossart R, et al. Steps to Take to Reduce Length of Hospital Stay in Patients With Lower Respiratory Tract Infections: A Prospective Cohort Study. Home Health Care Management & Practice. 2010;10:1-8.
21. Bundesamt für Gesundheit (BAG) EDdI: «Kennzahlen der Schweizer Spitäler 2004». www.bagadmin.ch. 2006 01.11.2006.
22. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72.
23. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American journal of respiratory and critical care medicine. 2001;163(7):1730-54. (Pubitemid 32578779)
24. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-50. (Pubitemid 27044625)
25. Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D - a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69(1):67-73. (Pubitemid 30410417)
26. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203-20. (Pubitemid 40353904)
27. Kuwabara H, Fushimi K: The impact of a new payment system with case-mix measurement on hospital practices for breast cancer patients in Japan. Health Policy. 2009;92(1):65-72.
28. Gilman BH: Hospital response to DRG refinements: the impact of multiple reimbursement incentives on inpatient length of stay. Health Econ. 2000;9(4):277-94.
29. Guertler C, Wirz B, Christ-Crain M. Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J. 2011;7(6):1439-46. Epub2010 Nov 11.